Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
04 oct. 2024 10h31 HE | Compass Therapeutics
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Abstract and Professional Community Excellence Award Receipients (Part 1)
ISHLT 2023 Annual Meeting Awards Showcase Advances in Treatment of Advanced Heart and Lung Disease Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
24 avr. 2023 05h00 HE | Medigene AG
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting
11 avr. 2023 10h45 HE | Medigene AG
Martinsried/Munich, April 11, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
16 mars 2023 05h00 HE | Medigene AG
Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Howard Eisen, MD
ISHLT Annual Meeting & Scientific Sessions to Convene International Transplant Community Next Month Chicago, IL, March 14, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) will host its 43rd Annual Meeting & Scientific Sessions on 19-22 April, 2023...
Studies with FCS Participation Highlighted at the 2022 San Antonio Breast Cancer Symposium
Florida Cancer Specialists & Research Institute Contributing to Rapid Advancements in Breast Cancer Treatment
13 déc. 2022 13h58 HE | Florida Cancer Specialists & Research Institute
Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) hematologists and medical oncologists were contributors to several presentations...
Featured Image for Secured Signing
Secured Signing's CEO Gal Thompson Introduces Notary Queue and Snapshot to Its Remote Online Notarization and Digital Signature SaaS Platform
06 déc. 2022 19h46 HE | Secured Signing
MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Secured Signing today announced the latest product updates and enhancements across its Remote Online Notarization and Digital Signature...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
12 juil. 2022 09h00 HE | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their...
Florida Cancer Specialists & Research Institute is well represented at the 2022 ASCO Annual Meeting.
Florida Cancer Specialists & Research Institute Presents Clinical Research Results at 2022 ASCO® Annual Meeting
03 juin 2022 09h57 HE | Florida Cancer Specialists & Research Institute
Fort Myers, Florida, June 03, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLS (FCS) physicians are presenting the outcomes of 33 clinical trials, the majority being...